DZ2237A1 - 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number
DZ2237A1
DZ2237A1 DZ970085A DZ970085A DZ2237A1 DZ 2237 A1 DZ2237 A1 DZ 2237A1 DZ 970085 A DZ970085 A DZ 970085A DZ 970085 A DZ970085 A DZ 970085A DZ 2237 A1 DZ2237 A1 DZ 2237A1
Authority
DZ
Algeria
Prior art keywords
preparation
new
pharmaceutical compositions
compositions containing
quinazolinones
Prior art date
Application number
DZ970085A
Other languages
English (en)
Inventor
Mark L Elliot
Wiliiard M Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2237A1 publication Critical patent/DZ2237A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
DZ970085A 1996-05-15 1997-05-14 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2237A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
DZ2237A1 true DZ2237A1 (fr) 2002-12-03

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970085A DZ2237A1 (fr) 1996-05-15 1997-05-14 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (39)

Country Link
US (1) US6303615B1 (fr)
EP (1) EP0901487B9 (fr)
JP (1) JP3241388B2 (fr)
KR (1) KR100375155B1 (fr)
CN (2) CN1103772C (fr)
AP (1) AP1148A (fr)
AR (1) AR007118A1 (fr)
AT (1) ATE242232T1 (fr)
AU (1) AU730503B2 (fr)
BG (1) BG102999A (fr)
BR (1) BR9709085A (fr)
CA (1) CA2252907C (fr)
CZ (1) CZ295565B6 (fr)
DE (1) DE69722613T2 (fr)
DK (1) DK0901487T3 (fr)
DZ (1) DZ2237A1 (fr)
EA (1) EA002905B1 (fr)
ES (1) ES2198546T3 (fr)
GT (1) GT199700049A (fr)
HK (1) HK1019607A1 (fr)
HN (1) HN1997000052A (fr)
HR (1) HRP970261B1 (fr)
HU (1) HUP9902148A3 (fr)
ID (1) ID17149A (fr)
IL (1) IL126589A (fr)
IS (1) IS4881A (fr)
MA (1) MA26430A1 (fr)
NO (1) NO985293L (fr)
OA (1) OA10918A (fr)
PL (1) PL330042A1 (fr)
PT (1) PT901487E (fr)
SI (1) SI0901487T1 (fr)
SK (1) SK284108B6 (fr)
TN (1) TNSN97087A1 (fr)
TR (1) TR199802296T2 (fr)
TW (1) TW539675B (fr)
WO (1) WO1997043276A1 (fr)
YU (1) YU19197A (fr)
ZA (1) ZA974156B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL335307A1 (en) * 1997-02-28 2000-04-10 Pfizer Prod Inc Atropoisomers of 3-heteroaryl-4(3h)-quinazolynes for treating neurodegenerative and traumatic states of central nervous system
ES2219866T3 (es) * 1997-02-28 2004-12-01 Pfizer Products Inc. Atropisomeros de 3-aril-4(3h)-quinazolinonas y su uso como antagonistas del receptor de ampa.
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (fr) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
US6825192B1 (en) 1999-02-15 2004-11-30 Eisai Co., Ltd. Heterodiazinone derivatives
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
AU2002366103A1 (en) 2001-11-19 2003-06-10 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2004009036A2 (fr) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Composes, compositions et procedes
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2007056124A2 (fr) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Composés destinés à moduler la fonction de trpv3
EP2079739A2 (fr) 2006-10-04 2009-07-22 Pfizer Products Inc. Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique
WO2008140750A1 (fr) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Composés modulant la fonction du trp v3
AU2008305581C1 (en) * 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009096667A2 (fr) 2008-01-30 2009-08-06 Shin Poong Pharmaceutical Co., Ltd. Nouveau dérivé de quinazoline-2,4-dione et compositions médicales pour la prophylaxie et le traitement de la maladie du nerf crânien contenant ledit dérivé
JP5794919B2 (ja) 2008-11-13 2015-10-14 ギリアード カリストガ エルエルシー 血液学的な悪性疾患のための療法
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
US9216177B2 (en) 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
CA2864305C (fr) 2012-03-05 2021-02-16 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (fr) 2013-12-20 2015-06-25 Gilead Calistoga Llc Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
WO2015191726A1 (fr) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
EP4096661A4 (fr) 2020-01-29 2024-03-06 Kamari Pharma Ltd. Composés et compositions pour leur utilisation dans le traitement de troubles cutanés

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (fr) 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE69401583T2 (de) 1993-05-06 1997-06-12 Novonordisk As [1,2,4-TRIAZOLO[4,3-a]CHINOXALINVERBINDUNGEN DEREN HERSTELLUNG UND VERWENDUNG
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
ES2219866T3 (es) 1997-02-28 2004-12-01 Pfizer Products Inc. Atropisomeros de 3-aril-4(3h)-quinazolinonas y su uso como antagonistas del receptor de ampa.

Also Published As

Publication number Publication date
YU19197A (sh) 1999-09-27
HRP970261B1 (en) 2003-06-30
DE69722613D1 (de) 2003-07-10
IS4881A (is) 1998-10-27
HUP9902148A2 (hu) 2000-04-28
JP3241388B2 (ja) 2001-12-25
WO1997043276A1 (fr) 1997-11-20
IL126589A0 (en) 1999-08-17
GT199700049A (es) 1998-10-21
SI0901487T1 (en) 2003-10-31
CZ352698A3 (cs) 1999-11-17
CN1103772C (zh) 2003-03-26
PL330042A1 (en) 1999-04-26
TNSN97087A1 (fr) 2005-03-15
US6303615B1 (en) 2001-10-16
EP0901487A1 (fr) 1999-03-17
CA2252907A1 (fr) 1997-11-20
AP1148A (en) 2003-02-28
CN1420114A (zh) 2003-05-28
NO985293D0 (no) 1998-11-13
AR007118A1 (es) 1999-10-13
NO985293L (no) 1999-01-13
EP0901487B9 (fr) 2004-09-29
SK284108B6 (sk) 2004-09-08
HRP970261A2 (en) 2000-12-31
CA2252907C (fr) 2005-05-17
BG102999A (en) 1999-09-30
TR199802296T2 (xx) 1999-02-22
KR20000011054A (ko) 2000-02-25
IL126589A (en) 2003-06-24
ZA974156B (en) 1998-11-16
KR100375155B1 (ko) 2003-08-19
PT901487E (pt) 2003-08-29
HN1997000052A (es) 1997-06-26
EA199800923A1 (ru) 1999-06-24
ATE242232T1 (de) 2003-06-15
ID17149A (id) 1997-12-04
JPH11514663A (ja) 1999-12-14
TW539675B (en) 2003-07-01
SK152098A3 (en) 2000-05-16
MA26430A1 (fr) 2004-12-20
AP9701003A0 (en) 1997-07-31
BR9709085A (pt) 1999-08-03
AU730503B2 (en) 2001-03-08
CN1218464A (zh) 1999-06-02
ES2198546T3 (es) 2004-02-01
EP0901487B1 (fr) 2003-06-04
AU1554997A (en) 1997-12-05
OA10918A (en) 2001-10-25
DE69722613T2 (de) 2004-05-13
EA002905B1 (ru) 2002-10-31
HK1019607A1 (en) 2000-02-18
CZ295565B6 (cs) 2005-08-17
DK0901487T3 (da) 2003-08-25
HUP9902148A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
DZ2237A1 (fr) 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA24484A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2465A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
MA26598A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2694290B1 (fr) Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
MA23899A1 (fr) Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr) Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.